Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.
about
The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathyThe Homophilic Domain - An Immunological ArchetypeScanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory MyopathiesPredicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic NeuritisIVIG regulates the survival of human but not mouse neutrophils.Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats.Efficacy of Intravenous Immunoglobulin in Neurological Diseases.Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin.Protection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation.Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy.bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression.IVIG-mediated effector functions in autoimmune and inflammatory diseases.Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.10% liquid human immunoglobulin (KIOVIG(®)) for immunomodulation in autoimmune disorders.The potential of intravenous immunoglobulins for cancer therapy: a road that is worth taking?Diagnostic and therapeutic strategies for management of autoimmune encephalopathies.Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer's disease.Biological roles of glycans.Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases.Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome.Severe refractory CIDP: a case series of 10 patients treated with bortezomib.Natural Antibodies: Next Steps Toward Translational Investigation.Therapeutic Potential of Intravenous Immunoglobulin in Acute Brain Injury.Dose-dependent inhibition of demyelination and microglia activation by IVIG.Novel approaches for the development of peripheral nerve regenerative therapies.ARTHUR ASBURY LECTURE: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of auto-immunity to nodal components.Immunoglobulin therapy ameliorates the phenotype and increases lifespan in the severely affected dystrophin-utrophin double knockout mice.An Overview on the Clinical Development of Tau-Based Therapeutics.
P2860
Q26743993-12BD5045-5847-478A-B869-D9C90C4D1FFDQ26752282-CF03C1ED-E97F-4FAF-93A5-CA957ADADBE2Q26798209-73C5BB6F-A48A-4CB4-803D-D7CA4BE20751Q27320796-23059641-30D7-4FBA-B3AD-3CDA5AAB4D66Q33683531-1328EFF1-7D1C-4C92-9F1C-C907AA9951C6Q36239584-033B5BE4-6906-4B3D-935F-8843438063A5Q36484438-B0CCE204-4B12-4B16-896B-DF873EAFDC06Q36500575-EBAA9D19-B887-4491-9A54-1F0815B2DE12Q36592223-B4E12D47-9FA2-42AA-B44D-9E40BBD0B88EQ37713650-A8265C42-AC2F-4A27-BFE0-A3364FFD6BEFQ38615353-03C1BD5B-03B7-4672-AD26-838DDCA7E402Q38699812-5B2732BF-64AB-4B7E-8D5D-0C3E5DF15662Q38729214-814E4C4E-B310-4687-ACC0-5CD5E320CD2EQ38820352-84940098-9019-420F-8049-CFDF6384FFB3Q38824186-F714EAAD-4925-4F6D-ACE9-B035E65E76A6Q38832800-0591B8E6-EB7E-4124-BE7A-B13FDA8B082FQ38864839-D410D097-B357-4D63-A26D-303821EC97F2Q38936714-514E3D5F-19EC-447F-B403-367098D4C02CQ39090725-15376A83-2AAC-4182-A467-774498583887Q39434973-DEB75CAE-A17C-427D-AE3B-7457CBF5B6F8Q39724271-078F8634-4149-496D-8BFE-D4539DEC4D87Q40081746-631840DB-54E5-4709-A875-EAD0DF163203Q40151268-612BEA9E-C31D-4A6C-9449-1BAC7175F14EQ41170285-821D90B2-1F09-4025-BD53-A1137445FE65Q41819438-E0A8415C-D27F-40B0-9423-76F496FE173FQ43099574-D5870297-817B-4BD8-AF82-111C5045FAE0Q47610103-07571910-DABB-4C43-89D1-8EF29630890CQ49644555-45DBAB61-9064-4037-8A45-AF284F0698D7Q52594209-94B85B2A-8D20-46DA-A545-3431BEFFC6A8
P2860
Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.
@en
type
label
Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.
@en
prefLabel
Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.
@en
P2860
P1476
Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.
@en
P2093
Marinos C Dalakas
P2860
P2888
P356
10.1038/NRNEUROL.2014.253
P407
P577
2015-01-06T00:00:00Z
P5875
P6179
1041560736